Scinai Immunotherapeutics Ltd ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.3MTTM through 31 Dec 2025
Net Income -$8.3MTTM through 31 Dec 2025
Free Cash Flow -$6.1MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Operating Margin | -575.3% |
| Net Margin | -638.5% |
Returns
-102.5%ROE
-71.4%ROA
Balance Sheet Health
Current Ratio1.30x
Net Debt$610K
Cash & Equivalents$1.7M
Quality Metrics
FCF Margin-461.9%
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $1.3M
Diluted EPSFY2025: $0.00
Dividend
No dividend
Capital Allocation
Capex Intensity1.8%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| CDMO Services | $1.3M | +85.7% | View detailsExpanded CDMO platform post year-end through the acquisition of Recipharm Israel and entry into a strategic commercial collaboration with Recipharm. |
| R&D (Therapeutics) | $0 | View detailsPursuing non-dilutive grants to fund PC111 and NanoAb programs. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.